Company Overview and News

53
5 Spinoff Stocks That Outperform Their Parents | InvestorPlace

2018-07-09 investorplace
Spinoff stocks long have been a group targeted by value investors. Well-known investor Joel Greenblatt is among those who look for value, particularly soon after the spin is complete.
ARNC.PR ARNC.PRB AA.PRB NC GOOG WMT GTN.A AAI AMZN IDT.WI RFL.WI AA IDT IDT ARNC LOGI CARS TGNA GTN HBB GOOGL AA.PR RFL VZ STRP NTGR

8
IDT Corporation (IDT) CEO Shmuel Jonas on Q3 2018 Results - Earnings Call Transcript

2018-06-05 seekingalpha
Good day, everyone. And welcome to the IDT Corporation's Third Quarter Fiscal Year 2018 Earnings Conference Call. In today's presentation, IDT's management will discuss IDT's financial and operational results for the three-month period ended April 30, 2018. During prepared remarks by IDT's Chief Executive Officer, Shmuel Jonas, all participants will be in listen-only mode [Operator Instructions]. After the prepared remarks, Marcelo Fischer, IDT's Senior Vice President of Finance and Chief Financial Officer of IDT Telecom will join Mr.
IDT IDT.WI RFL IDT RFL.WI

7
BRIEF-IDT says Chairman Jonas To Buy 2.5 Mln Shares of Class B Stock

2018-04-17 reuters
* IDT CORP - HOWARD JONAS HAS AGREED TO PURCHASE 2.5 MILLION SHARES OF CLASS B COMMON STOCK AT A PRICE PER SHARE OF $5.89
IDT IDT.WI IDT

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to ASX:IDT / IDT AUSTRALIA LIMITED on message board site Silicon Investor.

IDTI - an IC Play on Growth Markets IDT *(idtc) following this new issue?*
IDT, IDT.C and NTOP SI Diamond Technology (SIDT)
IDTC Options Players (losers and whiners) BACKDOOR, an IPOu003e IDTC,BRKT,BNYN,KLOC,NAVR
IDTC (for longs only) AcidTV wants your video!
IDTC - on the way to a new price? IDTI - Dark Horse For u002796 ?